Compare Ascendis Pharma A/S (ASND) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Coinbase Global, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Coinbase Global, Inc. trades at $157.13 (market cap $41.91B). The key difference: Coinbase Global, Inc. is far larger — about 2.4× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | COIN | |
|---|---|---|
Market Cap | $17.74B | $41.91B |
Sector | Health | Technology |
52-Week High | $277.18 | $419.78 |
52-Week Low | $163.32 | $141.09 |
Enterprise Value | $18.11B | $39.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
COIN trades at $159.07, up 0.4% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported mixed Q1 2026 earnings, missing estimates, but maintains strong revenue growth and a 73.32% gross margin. Analyst consensus remains bullish with a $230.15 price target, supported by recent regulatory developments like Circle's OCC trust bank approval (Reuters, 2026-07-10).
The outlook is cautiously optimistic given analyst support and improving cash flows, but risks include earnings volatility and regulatory uncertainty. Investment opportunity hinges on execution amid competitive pressures, with the stock offering potential upside if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
